211At-OKT10-B10
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for 211At-OKT10-B10, covering 2026-03-13 to 2026-03-13. Get the full timeline:
Most recent: Clinical Trial Update: ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma [Phase 1]